Navigation Links
First-Line Use of Abilify Has More Than Doubled Over the Past Year for the Treatment of Newly-Diagnosed Patients in Bipolar Disorder
Date:11/16/2010

BURLINGTON, Mass., Nov. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that first-line use of Bristol Myers-Squibb/Otsuka's Abilify has increased over the past year in newly-diagnosed patients from 4.1 percent patient share to 8.8 percent. According to Treatment Algorithms in Bipolar Disorder, uptake of Abilify in the first-line will continue among surveyed primary care physicians (PCPs): 26 percent of surveyed PCPs who prescribe Abilify indicate they expect to increase their first-line use of this agent over the next two years.

Overall use of Abilify is expected to increase over the next two years as well: 25 percent and 50 percent of surveyed psychiatrists and PCPs, respectively, expect their overall use of Abilify to increase. Surveyed physicians also indicate that use of AstraZeneca's Seroquel XR will grow substantially over the same time period with 28 percent of surveyed psychiatrists and 56 percent of surveyed PCPs expecting that their overall use of Seroquel XR will increase. Additional growth for Seroquel XR will be through greater use in the first line in both psychiatrists and PCPs: 29 percent of surveyed psychiatrists and 36 percent of surveyed PCPs who prescribe Seroquel XR indicate that they expect to increase their use of the agent in the first line over the next two years.

"In light of the anticipated increased use of Seroquel XR, we expect that AstraZeneca's Seroquel will lose some patient share to Seroquel XR, but that loss will not be large enough to unseat Seroquel from its lead position among atypicals. Uptake will be further challenged once generics of Seroquel become available in 2012," said Decision Resources Analysis Alana Simorellis, Ph.D. "Surveyed psychiatrists score Abilify preferentially in terms of ris
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
2. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
3. Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting
4. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
5. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
6. Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
7. Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkins Lymphoma
8. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
10. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
11. Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WHIPPANY, N.J. , March 4, 2015 /PRNewswire/ ... and Drug Administration (FDA) has accepted the company,s ... recombinant Factor VIII compound.  Bayer is seeking FDA ... Kovaltry™, for the treatment of hemophilia A in ... committed to continually bringing new therapies to hemophilia ...
(Date:3/4/2015)... , March 4, 2015  Heska Corporation (Nasdaq: ... Invites You to Join Its Fourth Quarter and Year ... 5, 2015 @ 9:00 a.m. (MST) / 11:00 a.m. ... End 2014 Earnings Call link on the front page ... on to the web at the address above.  Alternatively, ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Negative Pressure Wound Therapy Market (Conventional and ... Size, Share, Growth, Trends and Forecast 2014 - ... The global negative pressure wound therapy ... geography. By product types the NPWT market is ...
Breaking Medicine Technology:FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 2FDA Accepts Bayer's Biologics License Application for Investigational Treatment Option in Hemophilia A 3Webcast Alert: Heska Announces Fourth Quarter and Year End 2014 Earnings Conference Call Webcast 2Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2
... , PLEASANTON, Calif. , Jan. ... world leader in device-based mechanical circulatory support (MCS) therapies to ... has acquired an innovative catheter pump technology that it plans ... cardiac axial flow pump that can be delivered percutaneously in ...
... , HOUSTON , Jan. 25 ... peacefully in his home on January 19th after ... Woodyard began his tenure at eCardio as Vice President, Business ... development initiatives. He was also responsible for identifying, negotiating and ...
Cached Medicine Technology:Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 2Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 3Thoratec Announces Acquisition of Innovative Catheter-Based Heart Pump Technology 4Richard Woodyard, Vice President of Sales at eCardio, Loses Fight Against Cancer 2
(Date:3/4/2015)... March 04, 2015 FDA’s New Inspection ... **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. – ... generally know within four hours of an inspection whether ... is on their “good” list, they’ll merely ask for ... manufacturer is on the “bad” list, the manufacturer must ...
(Date:3/4/2015)... Concord, NH (PRWEB) March 04, 2015 ... the natural frozen food category, will attend this year’s ... from its newest product line. With this new line, ... meals in the natural channel, continues its commitment to ... the fastest growing frozen brand in the natural channel, ...
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The New ... and lyrical music, will be performed by the award-winning ... Estates, CA, this March 6-22, 2015, on Fridays, Saturdays ... at Peninsula High School (27118 Silver Spur Road, ... hour before the program or may be purchased on-line ...
(Date:3/4/2015)... Columbus is no stranger to drug addiction. The ... addiction, and suffers from the potential threat of Kratom. In ... DEA revealed that Kratom is a “drug of concern.” Although ... introduced herb from Southeast Asia acts as a stimulant in ... kratom foments symptoms similar to heroin withdrawal, and includes tremors, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 2Health News:Fastest Growing Frozen Brand in Natural Channel Showcases New Line at Expo West 2015 3Health News:The New Mel Brooks Musical Young Frankenstein Performance March 6-March 22, 2015, by the Award Winning Drama Department at Peninsula High School, Rolling Hills 2Health News:Columbus, OH Combats the Sale of Kratom as a Drug, Harbor Village Detox Stresses Caution 2
... , BATESVILLE, Ind., and ANDOVER, Mass., Sept. ... strategic partnership agreement to integrate the Radianse real-time location system ... this move, Hill-Rom intends to extend its leadership in health ... obstacles for health care customers as they consider high-precision, enterprise-wide ...
... ... Association (DIA) Study Endpoints Special Interest Area Community (SIAC) will host Measuring Study Endpoints ... Caregiver from October 26-27, 2009 in New Orleans, LA. , ... Horsham, PA (Vocus) September 2, 2009 ...
... Sept. 2 The following is an updated GlaxoSmithKline Consumer Healthcare statement ... orlistat: , , On August 24th the FDA ... serious adverse events. , , To view the Multimedia ... It,s important consumers know that alli is safe and effective ...
... , , , ... Sept. 2 /PRNewswire-FirstCall/ -- ... that is developing and marketing Levulan(R) Photodynamic Therapy (PDT) and other ... Doman, President and Chief Executive Officer, will present a corporate overview ...
... on their calls , TUESDAY, Sept. 1 (HealthDay ... research suggests they can appreciate music inspired by the ... similar to soothing monkey calls, the animals moved less ... distress calls, they became anxious. , This may not ...
... N.C., Sept. 2 Anpath Group, Inc. (OTC Bulletin Board: ANPG), ... joined the Board of Directors. , , Dr. ... care, specifically with HIV treatment and immunology. Currently he is ... Academy of HIV Medicine. In 2000, he founded his current ...
Cached Medicine News:Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 2Health News:Key Stakeholders to Discuss Regulatory Issues Related to the Use of Study Endpoints in Multinational Clinical Trials 3Health News:Video: FDA States Consumers Should Continue to Use alli 2Health News:DUSA Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2Health News:Scientists Make Sweet Monkey Music 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 2Health News:Dr. William J. Robbins Joins Anpath Group, Inc. Board of Directors 3
... HeartMate II Left Ventricular Assist System (LVAS) ... shown to restore hemodynamic function and improve ... the rotary action of a single-moving part, ... full circulatory support by pumping blood from ...
... for movement is critical ... wheelchairs. Thats why this ... technology to do just ... state-of-the-art technology, these wheelchair ...
... standard to extra-wide wheelchairs (18" to 43") ... heavy-duty, anodized aluminum weighing platform is equipped ... easy access for large patients. Weight is ... readout. The 6772 has the unique features ...
When patients are less mobile our ProPlus™ Stand-On Scale with built-in wheels moves easily to them. Extremely durable and safe, the easy grip handrail and non-skid platform provide added suppo...
Medicine Products: